基层医院采用国产尿激酶静脉溶栓治疗急性心肌梗死72例效果分析  

Efficacy analysis of domestic Urokinase intravenous thrombolysis in the treatment of 72 cases of acute myocardial infarction in primary hospital

作　　者：黄向荣 

机构地区：[1]广东省韶关市乳源瑶族自治县人民医院急诊科,广东乳源512700

出　　处：《中国当代医药》2016年第24期118-120,共3页China Modern Medicine

摘　　要：目的探讨国产尿激酶静脉溶栓治疗急性心肌梗死的效果。方法选取2013年2月~2014年6月在我院就诊的144例急性心肌梗死患者作为研究对象,随机分为对照组和观察组,各72例。观察组给予国产尿激酶静脉溶栓治疗,对照组不溶栓治疗。比较两组的胸痛发生率、血管再通率以及病死率。结果观察组治疗后的胸痛发生率显著低于对照组,差异有统计学意义(P<0.01)。观察组的心律失常发生率显著高于对照组,差异有统计学意义(P<0.01)。观察组的血管再通率为75.00%,显著高于高于对照组的9.72%,差异有统计学意义(P<0.01)。观察组的病死率为5.56%,显著低于对照组的29.17%,差异有统计学意义(P<0.01)。结论国产尿激酶静脉溶栓治疗急性心肌梗死效果显著,值得基层医院推广应用。Objective To explore the effect of intravenous thrombolysis with domestic Urokinase in the treatment of a- cute myocardial infarction.Methods 144 cases of acute myocardial infarction from February 2013 to June 2014 in our h^spital were selected and randomly divided into the control group and the observation group,72 cases in each group. The observation group was given domestic Urokinase intravenous thrombolytic therapy,the control group was not given thrombolysis treatment.The incidence rate of chest pain,vascular patency rate and mortality rate in the two groups was compared.Results The incidence rate of chest pain after treatment in the observation group was lower than that in the control group after treatment,with significant difference （P〈0.01）.The incidence rate of arrhythmia in the observation group was higher than that in the control group,with significant difference （P〈0.01）.The vascular patency rate of the observation group was 75.00%,which was higher than 9.72% of the control group,with significant difference （P〈0.01）.The mortality rate of the observation group was 5.56%,which was lower than 29.17% of the control group,with significant difference （P〈0.01）.Conclusion Domestic Urokinase intravenous thrombolysis in the treatment of acute myocardial infarction has significant effect,it is worthy of promotion and application in primary hospital.

关 键 词：国产尿激酶 静脉溶栓 急性心肌梗死 基层医院 

分 类 号：R541.4[医药卫生—心血管疾病]